1. Scrip

Hanmi In Tough Spot After Sanofi Efpeglenatide U-Turn

New Partners, Strategy Needed?

 
• By Jung Won Shin

Sanofi’s decision to return to originator Hanmi all rights to the novel diabetes candidate efpeglenatide, which is in global Phase III trials, has placed the South Korean pharma in a difficult spot. Unless there are some surprisingly positive data, finding a major global partner for commercialization may be tough.

Broken deal
Hanmi Hopes To Find New Partner After Comparative Study Ends • Source: Shutterstock

Sanofi has decided to return all development and commercialization rights to efpeglenatide to South Korean originator Hanmi Pharmaceutical Co. Ltd., as part of a decision by the French group last December not to commercialize the once-weekly GLP-1 receptor agonist as part of a wider exit from the diabetes and cardiovascular areas.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia